YS Biopharma Co., Ltd. announced that the Company's Board of Directors (the "Board") has approved Ms. Rui Yu as the new Chairperson of its Audit Committee, as a member of its Compensation Committee, and as a member of the Nominating and Corporate Governance Committee on January 7, 2024 (Beijing Time), with immediate effect. Ms. Yu currently serves as a partner at Oceanpine Capital, a position she has held since 2021. Prior to that, she served as a managing director at China Renaissance Group and vice president and head of China healthcare research at Gerson Lehman Group.

Ms. Yu received her Bachelor of Science degree from Guangdong Pharmaceutical University, her Master of Science degree from the University of Missouri School of Medicine, and her MBA from the University of Chicago Booth School of Business with concentrations in finance, accounting and entrepreneurship. Accordingly, the membership of each Board Committee will be as follows: Audit Committee: Rui Yu (Chairperson), Viren Mehta, and Shaojing Tong; Compensation Committee: Viren Mehta (Chairperson), Ajit Shetty, Shaojing Tong, and Rui Yu and Nominating and Corporate Governance Committee: Ajit Shetty (Chairperson), Viren Mehta, Rui Yu, and Yi Zhang.